Coronavirus vaccine shows promising early results

Coronavirus vaccine shows promising early results

Researchers studied blood samples from the test subjects to determine whether the vaccine helped them generate antibodies that could bind to the virus and ones that can fight off an infection. Some use the same technology as Moderna, which involves a segment of genetic material from the virus called messenger RNA, or mRNA.

As with any vaccine, the goal with coronavirus is to get the immune system to produce antibodies that can eliminate the virus. People in the highest dose group received only one inoculation. Moderna tested three different vaccine dosages across 45 study participants, and all of them have developed neutralizing antibodies.

A pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle, on March 16, 2020.

Two weeks after patients received the final dose at the 25 and 100 mcg levels, eight saw their antibody levels rise to about the same level as patients who already recovered from COVID-19, according to the report. There were 45 people involved in these three arms, though neutralizing antibody data are only available at this point for the first four patients each of the 25 microgram and 100 microgram cohorts.

The U.S. Food and Drug Administration (FDA) has given the biotech firm a green light to begin their second phase of trials which entails trying out their experimental vaccine on at least 600 volunteers.

After the results, the company has dropped the idea of administering 250 mcg doses to participants. Federal officials recently cleared the vaccine for phase two trials.

Morgan Stanley is the sole book-running manager for the offering that allows underwriters to buy an additional 2.64 million shares, the statement said.

He also said the company now can better choose the vaccine amount needed for further experiments.

"With today's positive interim Phase I data and the positive data in the mouse challenge model, the Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase III study in July and, if successful, file a BLA", said Stéphane Bancel, Chief Executive Officer at Moderna.

"There is also growing evidence that the global economy troughed in mid-April with high frequency data such as Apple/Google mobility pointing to a pick-up in activity".

Earlier this month, President Donald Trump said he felt very confident that the US would have a vaccine to fight the new coronavirus by 2021. All adverse events have been transient and self-resolving.

Talking about vaccines, it is generally known that it would take years and several breakthroughs to be able to find the right formula for the vaccine to work for the entire human population. Even if it was, promising results from Phase 1 trials often don't translate to effective, approved treatments down the line.

Related Articles